WHO to develop plan to curb artemisinin resistance

Burr, William
February 2011
CMAJ: Canadian Medical Association Journal;2/8/2011, Vol. 183 Issue 2, pE81
Academic Journal
The article focuses on the Global Plan for Artemisinin Resistance Containment of the World Health Organization (WHO). The World Malaria Report 2010 suggests that advances against malaria disease is dependent on artemisinin-based combination therapies (ACTs) since it is the only treatment option available for the disease. Brian Ward of the Centre for the Study of Host Resistance in Quebec says that political and civic unrest pose a hindrance to further the reduction of malaria cases.


Related Articles

  • Artemesinin-based Combination Therapy in Malaria Non-endemic Areas. POTHAPREGADA, SRIRAM // Indian Pediatrics;Jul2014, Vol. 51 Issue 7, p588 

    The article offers the author's views on the use of artemesinin combination therapy (ACT) for the treatment of malaria in non-endemic areas in India. The author says that the National Vector-Borne Disease Control Programme (NVBDCP), the National Antimalarial Programme (NAMP) and the World Health...

  • Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Frosch, Anne E. P.; Venkatesan, Meera; Laufer, Miriam K. // Malaria Journal;2011 Supplement 1, Vol. 10 Issue Suppl 1, p116 

    Background: As a result of widespread chloroquine and sulphadoxine-pyrimethamine (SP) resistance, 90% of sub- Saharan African countries had adopted policies of artemisinin-based combination therapy (ACT) for treatment of uncomplicated malaria by 2007. In Malawi, cessation of chloroquine use was...

  • Spread of artemisinin resistance may hinder efforts to control malaria.  // Infectious Diseases in Children;Jan2010, Vol. 23 Issue 1, p34 

    The article reports on the spread of resistance to the antimalarial drug artemisinin, which may hinder efforts to control malaria caused by the Plasmodium falciparum parasite.

  • The global pipeline of new medicines for the control and elimination of malaria. Anthony, Melinda P; Burrows, Jeremy N; Duparc, Stephan; JMoehrle, Joerg; Wells, Timothy NC // Malaria Journal;2012, Vol. 11 Issue 1, p316 

    Abstract: Over the past decade, there has been a transformation in the portfolio of medicines to combat malaria. New fixed-dose artemisinin combination therapy is available, with four different types having received approval from Stringent Regulatory Authorities or the World Health Organization...

  • The pharmaceutical death-ride of dihydroartemisinin. Jansen, Frans Herwig // Malaria Journal;2010, Vol. 9, p212 

    In the 2010 second edition of WHO's guidelines for the treatment of malaria, the relatively new fixed dose combination dihydroartemisinin-piperaquine is included as one of the recommended artemisinin combination therapies. However, experimental testing demonstrates that, due to its intrinsic...

  • Following WHO's recent call to end artemisinin monotherapy, 13 pharmaceutical companies have agreed to stop marketing artemisinin single-drug formulations.  // PharmacoEconomics & Outcomes News;5/20/2006, Issue 503, p3 

    The article reports on the announcement made by the World Health Organization (WHO) that 13 pharmaceutical firms have agreed to stop marketing artemisinin single-drug formulations. It cites that the firms that have agreed to comply with the recommendations of WHO will direct their marketing...

  • Looking ahead.  // Bulletin of the World Health Organization;Jan2011, Vol. 89 Issue 1, p5 

    The article presents a calendar of world health-related meetings and events for January, February, and March 2011, noting the January launch of a global plan for elimination of resistance to the malaria drug artemisinin, the World Health Organization (WHO) executive board meeting in February,...

  • Artemisinin Resistance: Why Now? Chen, Lin H. // Travel Medicine Advisor;Oct2009, Vol. 19 Issue 10, p56 

    Resistance of malaria parasites to artemisinin has been documented both in vivo and in vitro in western Cambodia, probably because of artemisinin monotherapy. Artemisinin-based combination therapies may delay the development of resistance and should be used instead of monotherapy.

  • Respondent-driven sampling on the Thailand- Cambodia border. I. Can malaria cases be contained in mobile migrant workers? Khamsiriwatchara, Amnat; Wangroongsarb, Piyaporn; Thwing, Julie; Eliades, James; Satimai, Wichai; Delacollette, Charles; Kaewkungwal, Jaranit // Malaria Journal;2011 Supplement 1, Vol. 10 Issue Suppl 1, p120 

    Background: Reliable information on mobility patterns of migrants is a crucial part of the strategy to contain the spread of artemisinin-resistant malaria parasites in South-East Asia, and may also be helpful to efforts to address other public health problems for migrants and members of host...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics